Bavarian Nordic

BAVA.CO Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$195.70

+1.37% today

52W: $123.30 – $244.80

52W Low: $123.30 Position: 59.6% 52W High: $244.80

🔗 Compare Brokers

Key Metrics

P/E Ratio

11.13x

Price-to-Earnings

Forward P/E

17.96x

Forward Price/Earnings

P/S Ratio

2.42x

Price-to-Sales

EV/EBITDA

7.32x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$15.1B

Market Capitalization

Revenue Growth

-30.7%

YoY Revenue Growth

Profit Margin

22.03%

Net profit margin

ROE

11.33%

Return on Equity

Beta

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

287,593

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

3 analysts

Avg. Price Target

$268.33

+37.11% upside

Target Range

$250.00 – $280.00

About the Company

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is he

Sector: Healthcare Industry: Biotechnology Country: Denmark Employees: 1,692 Exchange: CPH